Evidence map›Paper›PMID 18453283›Full record

ReviewScience progress2008

Towards a cure for dementia: the role of axonal transport in Alzheimer's disease.

Richard J Wilson

Open access · greenAbstract readReview
In one paragraph

Review in Science progress, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Richard J Wilsonrichard.j.wilson@warwick.ac.uk
Artificial Intelligence in Medicine (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease is an incurable, fatal illness characterised by years of progressive mental decline. It afflicts half a million people in the UK--more than any other dementia. The primary risk factor is old age so this number is rising as we live longer. Current treatment is palliative while more potent drugs have encountered problems during clinical trials. It is known that the disease results from brain deterioration associated with the formation of microscopic lesions. Genetic mutations cause a small minority of cases but our knowledge of the underlying biological mechanisms is limited. The key to improved understanding may be a process vital to brain cells called axonal transport. Disruption of axonal transport seems to be an early event in the progression of the disease and is linked to lesion formation and brain dysfunction so a full investigation of this process should lead to a cure, if not prevention.

Indexed as

Axonal TransportAlzheimer DiseaseAmyloidHumanstau ProteinsAmyloidtau Proteins

Identifiers

PMID18453283
PMCPMC10367473
OpenAlexW1972113358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.